Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view

by Staff GBAF Publications Ltd
0 comment

GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view

(Reuters) – Consumer healthcare group Haleon expects 2023 organic revenue growth towards the upper end of its 4%-6% forecast, it said on Thursday, on strong demand and the restocking of its respiratory health products due to a bad cold and flu season.

The company, the world’s biggest standalone consumer health business that sells non-prescription drugs, vitamins and oral care products, kept the rest of its full-year 2023 outlook unchanged.

Haleon was carved out of British drugmaker GSK in July last year.


(Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman)